Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11662214 | 0.74 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL8041868 | 0.70 | HTR6 (0.36) | TSHRALDH1A1HPGDHSD17B10PTPRC | |
| Indene SCHEMBL1722574 | 0.68 | CA1 (0.47) | CYP3A4TSHRALDH1A1HPGDTDP1 | |
| SCHEMBL15899337 | 0.67 | CD44 (0.32) | TSHRALDH1A1 | |
| SCHEMBL27944321 | 0.65 | ADORA2A (0.42) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL3036922 | 0.65 | CYP3A4 (0.57) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL28008381 | 0.64 | CA1 (0.37) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL9321634 | 0.64 | ADORA2A (0.37) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL972273 | 0.62 | ALDH1A1 (0.35) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL10462361 | 0.62 | ADORA2A (0.44) | CYP3A4TSHRALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3966703-A | Asymmetrical frisazo dyestuffs derived from diazotized 2,7-diamino-carbazole | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | claimed |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4146654-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224636-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2021-11-11 | — | — | WO | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-8575154-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8138130-B2 | Fused-ring aromatic amine based wear and oxidation inhibitors for lubricants | CHEVRON ORONITE COMPANY LLC (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| EP-1707616-B1 | Fused-ring aromatic amine based wear and oxidation inhibitors for lubricants | CHEVRON ORONITE CO (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20060223717-A1 | Fused-ring aromatic amine based wear and oxidation inhibitors for lubricants | CHEVRON ORONITE COMPANY LLC | 2006-10-05 | — | — | US | disclosed |
| EP-1707616-A2 | Fused-ring aromatic amine based wear and oxidation inhibitors for lubricants | Chevron Oronite Company LLC (US) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | CYP3A4 1457/4885TSHR 58/4885ALDH1A1 431/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN2 | CYP3A4 2364/4885TSHR 4625/4885ALDH1A1 1313/4885 |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | CYP3A4 1457/4885TSHR 58/4885ALDH1A1 431/4885 |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CYP3A4 1896/4885TSHR 1089/4885ALDH1A1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.